LifeBio Memory: Development of a Reminiscence Therapy Online Platform With Machine Learning to Increase Engagement (LifeBio Memory)
調査の概要
詳細な説明
Alzheimer's Disease and Related Dementias (ADRD) are becoming more prevalent in the United States. It is expected that the number of people affected will increase to 7.2 million by 2025 and 11.2 million by 2040. This is accompanied by a staggering cost of care, amounting to $345 billion annually in the US alone, with Medicare and Medicaid accounting for $222 billion of that amount. Globally, the cost of dementia is estimated to be over $1.3 trillion in 2021, and it is expected to rise to $2.8 trillion by 2030.
The effectiveness of LifeBioMEMORY (LBM) technology has shown promise in increasing engagement and social support through life story capture and RT opportunities among institutionalized older adults with cognitive impairment and formal caregivers. More than 1,000 individuals have been voice recorded in nursing home or residential living settings as a result of LBM Phase II SBIR grant. LBM's Phase IIB renewal application is to continue research and development and to advance toward further commercialization, with NIA's commitment to funding R&D for interventions for prevention or treatment of MCI and ADRD. With LMM Phase IIB based on RT and now capturing life stories in older adults' own voices, the investigtors propose to build and then validate an enhanced multi-language version of the LBM app with a diverse, non-institutionalized population to investigate linguistic and cultural appropriateness, focusing on Hispanic/Latinx, Asian American (as one of subgroups, Korean), Black or African-American, and non-Hispanic White older adults with MCI or at risk of MCI and their informal caregivers.
The specific aims of this SBIR application are to: 1) Update the LBM for culturally relevant multi-lingual support, 2) Assess its usability, and 3) Evaluate its feasibility, acceptability, and initial efficacy through a randomized waitlist-controlled trial using a mixed methods approach among diverse racial and ethnic dyads, each consisting of an older adult participant (with MCI or at risk of MCI) and an informal caregiver. This involves 84 older adult participants and 84 informal caregivers, including 21 Hispanic/Latinx, 21 Korean, 21 Black or African American, and 21 non-Hispanic White dyads. Outcomes such as health-related quality of life, depression, relationship closeness, and loneliness will be measured at baseline, 4 weeks post-follow-up, and 12 weeks post-follow-up. Additionally, user activities and qualitative interviews will be used to understand user experience, leading to recommended changes to the LBM interface by LifeBio as a result of Aims 2 and 3.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Kyeung Mi Oh, PhD
- 電話番号：703 993 4550
- メール：koh5@gmu.edu
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
The investigators will enroll a total of 84 older adult participants and 84 informal caregivers across the 84 dyads, comprising 21 Hispanic/Latino dyads, 21 Korean dyads, 21 Black dyads, and 21 Non-Hispanic White dyads.
The inclusion and exclusion criteria for older adult participants are:
- Self-identified as Hispanic/Latino, Korean, Black/African American, and Non-Hispanic White
- Speak and read Spanish, Korean, or English
- Aged 60 years and older, with Montreal Cognitive Assessment (MoCA) test scores ranging 18-30 (with MCI: 18-25, or at risk for MCI: 26-30)
- Have a local or in-home informal caregiver who can participate who is age 18 or older
- No pre-existing acute psychotic disease or critical illness
- Consent to participate
The inclusion and exclusion criteria for informal caregivers are:
- Self-identified as Hispanic/Latino, Korean, Black/African American, and Non-Hispanic White
- Speak and read Spanish, Korean, or English
- Aged 18 years and older
- Currently serving as the primary informal caregiver for older adults aged 60 or older
- No pre-existing acute psychotic disease or critical illness
- Consent to participate
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：防止
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的：LifeBio Memory (LBM) digital reminiscence intervention
Participants will access the LifeBio Memory (LBM) digital reminiscence platform using a mobile phone or tablet.
Informal caregivers will complete a brief training.
During Weeks 1-2, dyads will complete at least two weekly sessions recording the older adult's life stories using structured prompts.
During Weeks 3-5, dyads will complete one weekly reminiscence and social engagement session.
In Week 6, participants will receive personalized LifeBio story materials, including a Life Story Book, Snapshot, and story summary.
|
LifeBioMEMORY (LBM) is a multilingual digital reminiscence therapy platform that guides older adults through life story sharing using culturally relevant prompts, photos, and voice recording in Spanish, Korean, or English.
The app includes "My Story" and "Fun Things to Do" features to support reminiscence and engagement while capturing personal narratives.
Using machine learning, LBM generates personalized Life Story Books and summaries in the preferred language of the older adult and informal caregiver, with electronic and printed copies available.
The intervention is designed to promote social engagement, strengthen caregiver relationships, and support person-centered care.
|
|
アクティブコンパレータ：Waitlist Control (Delayed LBM digital reminiscence intervention)
Participants will receive general education on brain health and information about available local social services during the control period.
After the control period, participants will participate in the LifeBio Memory (LBM) App intervention.
|
LifeBioMEMORY (LBM) is a multilingual digital reminiscence therapy platform that guides older adults through life story sharing using culturally relevant prompts, photos, and voice recording in Spanish, Korean, or English.
The app includes "My Story" and "Fun Things to Do" features to support reminiscence and engagement while capturing personal narratives.
Using machine learning, LBM generates personalized Life Story Books and summaries in the preferred language of the older adult and informal caregiver, with electronic and printed copies available.
The intervention is designed to promote social engagement, strengthen caregiver relationships, and support person-centered care.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Primary Outcome
時間枠：Assessments will be conducted at baseline, 6 weeks, and 10 weeks.
|
Health-Related Quality of Life (SF-12 Physical and Mental Component Summary Scores)
|
Assessments will be conducted at baseline, 6 weeks, and 10 weeks.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Center for Epidemiologic Studies Depression Scale (CES-D)
時間枠：Assessments will be conducted at baseline, 6 weeks, and 10 weeks.
|
The Center for Epidemiologic Studies Depression Scale (CES-D) measures depressive symptoms.
Total scores range from 0 to 60, with higher scores indicating greater depressive symptoms (worse outcome).
|
Assessments will be conducted at baseline, 6 weeks, and 10 weeks.
|
|
Relationship Closeness Scale (RCS)
時間枠：Assessments will be conducted at baseline, 6 weeks, and 10 weeks.
|
The Relationship Closeness Scale (RCS) measures perceived emotional closeness and relationship quality between the caregiver and care recipient.
Total scores range from 6 to 24, with higher scores indicating greater relationship closeness (better outcome).
|
Assessments will be conducted at baseline, 6 weeks, and 10 weeks.
|
|
UCLA Loneliness Scale
時間枠：Assessments will be conducted at baseline, 6 weeks, and 10 weeks.
|
The 3-Item UCLA Loneliness Scale (UCLA-LS-3) measures perceived loneliness and social isolation.
Total scores range from 3 to 9, with higher scores indicating greater loneliness (worse outcome).Time Frame: Assessments will be conducted at baseline, 6 weeks, and 10 weeks.
|
Assessments will be conducted at baseline, 6 weeks, and 10 weeks.
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。